Augmentin and Ectropion - a phase IV clinical study of FDA data
Summary:
We study 43,034 people who take Augmentin (amoxicillin; clavulanate potassium) or have Ectropion. No report of Ectropion is found in people who take Augmentin.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
What is Augmentin?
Augmentin has active ingredients of amoxicillin; clavulanate potassium. It is often used in sinusitis. eHealthMe is studying from 42,620 Augmentin users. Check the latest studies of Augmentin.
What is Ectropion?
Ectropion (lower eyelid turns outwards) is found to be associated with 85 drugs and 142 conditions by eHealthMe. Check the latest studies of Ectropion.
No report is found.
Do you take Augmentin and have Ectropion?
- Check whether Ectropion is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Augmentin:
- Augmentin (42,620 reports)
Ectropion treatments and more:
- Ectropion (414 reports)
How severe was Ectropion and when was it recovered:
Expand to all the drugs that have ingredients of amoxicillin; clavulanate potassium:
Browse all side effects of Augmentin:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Ectropion:
Browse all the conditions that are associated with Ectropion:
How the study uses the data?
The study uses data from the FDA. It is based on amoxicillin; clavulanate potassium (the active ingredients of Augmentin) and Augmentin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Pantoprazole Sodium and Hyzaar - now
- Could Clopra cause Blood Creatinine Increased? - a second ago
- Could Cisplatin cause Convulsions? - a second ago
- Drug interactions of Zolpidem Tartrate and Inlyta - 2 seconds ago
- Drug interactions of Magnesium and Menatetrenone - 7 seconds ago
- Drug interactions of Valacyclovir Hydrochloride and Treanda - 13 seconds ago
- Could Atacand cause Skin Tightness? - 15 seconds ago
- Could Cardizem cause Muscle Function Loss? - 17 seconds ago
- Could Doxycycline cause Seasonal Allergy? - 17 seconds ago
- Drug interactions of Donepezil and Gammagard - 17 seconds ago